BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Genopole® Creation Of A Biomanufacturing Center For Recombinant Proteins And Monoclonal Antibodies


9/25/2006 10:09:19 AM

EVRY, France, September 25 /PRNewswire/ -- The Genopole(R) biopark and the MAbgene company have announced the signature of a collaboration agreement for the creation and operation of a biomanufacturing center on the Genopole(R) Evry biocluster. By late 2007, the Center will produce recombinant proteins and monoclonal antibodies to GMP* standards. The objective is to promote the development of the cluster's biotech companies and meet the needs of research labs and the pharmaceutical industry. By operating in synergy with the existing Genethon viral vector production unit, the new Center and its associated projects will position Genopole(R) as the benchmark for biomanufacturing in France.

* Good Manufacturing Practice

The world biopharmaceutical market (with a forecast turnover of 114 billion USD by 2010, 14% of the global pharma market) is generating significant unmet needs, and France is lagging behind in terms of clinical-grade biomanufacturing sites. The Genopole(R) Biomanufacturing Center (which will come onstream in Evry by late 2007) should meet the needs of French and Europe-based biotech companies which currently have difficulty producing their lead molecules.

The biomanufacturing unit will use modified animal cells to produce batches of GMP-grade recombinant proteins and monoclonal antibodies. The batches will be employed in preclinical animal testing and Phase II clinical trials (and up to and including Phase III for orphan drug trials). The 1,300 m2 unit will be equipped with bioreactors 300 and 1700 liters and will produce 8 batches per year, ranging from 1 and 100 grams of purified protein.

A number of related projects are in Genopole(R)'s pipeline: the creation of a cell engineering service company and a formulation & aseptic packaging unit. Genopole(R) and MAbgene will together review opportunities to diversify their production technologies, which could result in the establishment of a second biomanufacturing center based on yeast-, bacteria- or plant cell-based techniques, whilst also opening out into sectors other than healthcare.

Register now for the International Symposium "New Perspectives in GMP Biomanufacturing"!

On October 24th, Genopole(R) (in association with EuroBiO 2006) is organizing an international symposium entitled "New Perspectives in GMP Biomanufacturing". The full program and registration details can be found at www.genopole.fr/bioproduction/

For more information: www.genopole.frwww.mabgene.com Genopole(R) Press Contact: Benedicte Robert +33-1-60-87-83-10 benedicte.robert@genopole.fr

Genopole

CONTACT: Genopole(R) Press Contact: Benedicte Robert, +33-1-60-87-83-10,benedicte.robert@genopole.fr



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES